Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism

Fig. 2

HDAC inhibitor ITF2357 inhibits the expression of HDAC2 and enhances the chemotherapeutic effect of Pem on NSCLC. A The protein expression of HDAC2 in a wild type-KARS NSCLC cell line H1299 and a mut-KARS NSCLC cell line A549 was detected by Western blot after different treatment. B The viability of cells was detected by MTT assay at different concentrations of ITF2357 or Pem. C The migration of cells upon different treatments was detected by Transwell assay. D The invasion of cells upon different treatments was detected by Transwell assay. E The apoptosis of cells upon different treatments was detected by flow cytometry. F The change of tumor size in mice upon different treatments (n = 5). G The weight analysis of tumors in mice upon different treatments (n = 5). **p < 0.05. ***p < 0.01. ****p < 0.001. Data among multiple groups were compared by one-way ANOVA, followed by Tukey’s post hoc tests. Data among multiple groups at different time points were compared by repeated measures ANOVA, followed by Bonferroni post hoc tests. Cellular experiments were repeated three times

Back to article page